How is V. cholerae lifestyle switching controlled?

如何控制霍乱弧菌生活方式的改变?

基本信息

  • 批准号:
    BB/N005961/1
  • 负责人:
  • 金额:
    $ 45.02万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2016
  • 资助国家:
    英国
  • 起止时间:
    2016 至 无数据
  • 项目状态:
    已结题

项目摘要

Vibrio cholerae is a bacterium. It is the biological agent that causes Cholera, a severe form of diarrhoea. Worldwide, approximately 4 million people are infected by V. cholerae every year. This results in hundreds of thousands of fatalities. Many cases are attributable to an ongoing global pandemic, the 7th to sweep our planet in recorded history. However, disease is also associated with local epidemics; the upsurge of Cholera cases in Haiti, following the 2010 earthquake, being of note. The annual financial cost associated with V. cholerae infections exceeds $3 billion annually. Hence, there is significant commercial interest in solving the "Cholera problem". At present, epidemics may be controlled by vaccinating the population in affected areas. However, currently available Cholera vaccines are poorly effective. Consequently, industrial operations worldwide are identifying strategies to develop better vaccines. The growing problem of resistance to antimicrobial agents is also fueling this trend. The ability of V. cholerae to persist in the environment, and cause disease, is dependent on exploitation of two different environmental niches. Principally, V. cholerae is an aquatic organism that colonises the surface of crustaceans. In this situation, the bacterium's primary source of nutrition is chitin; a component of the shellfish exoskeleton. Thus, V. cholerae forms biofilms on such surfaces. Conversely, when V. cholerae is ingested by fish, or humans, the bacterium's lifestyle is "reprogrammed" so that it can colonise the host. This is beneficial to the bacterium since it can multiply rapidly in hosts before being shed back into the environment. In humans this process is associated with the disease known as Cholera. Understanding how V. cholerae adapts to its different environments is therefore of great interest.In recent work we have shown how applying the next generation of experimental tools can rapidly progress our understanding of bacterial pathogens. We propose to apply such tools to understand lifestyle switching in V. cholerae. Ultimately, by picking apart the control of lifestyle switching, and redesigning V. cholerae to regulate this process differently, we hope to stimulate a new era of vaccine design. We expect that this approach will be applicable to many diseases caused by bacteria. We have identified UK based biopharma likely to benefit from these advances and will liaise closely with them throughout the project. The purpose of this interaction is to maximise the impact of our work and to exploit opportunities that arise for commercialisation. In summary, we will study a globally important pathogen and develop strategies applicable to the control of all bacteria. Importantly, this application comes at a time when alternatives to antibiotics are being sought and the window of opportunity to act is open. We have already fostered links with important "end-users" of our data to maximise the economic impact of our work.
霍乱弧菌是一种细菌。它是引起霍乱的生物制剂,霍乱是一种严重的腹泻形式。全世界每年约有400万人感染霍乱弧菌。这导致数十万人死亡。许多病例可归因于正在进行的全球大流行病,这是有史以来第七次席卷我们的星球。然而,疾病也与地方流行病有关;值得注意的是,2010年地震后海地霍乱病例激增。与霍乱弧菌感染相关的年度财务成本每年超过30亿美元。因此,解决“霍乱问题”具有重大的商业利益。目前,可以通过对受影响地区的人口接种疫苗来控制流行病。然而,目前可用的霍乱疫苗效果不佳。因此,全世界的工业界正在确定开发更好疫苗的战略。日益严重的抗微生物药物耐药性问题也助长了这一趋势。霍乱弧菌在环境中持续存在并引起疾病的能力取决于对两种不同环境生态位的利用。主要地,霍乱弧菌是一种水生生物,定居在甲壳类动物的表面。在这种情况下,细菌的主要营养来源是甲壳素,甲壳素是贝类外骨骼的一种成分。因此,霍乱弧菌在这些表面上形成生物膜。相反,当鱼类或人类摄入霍乱弧菌时,细菌的生活方式被“重新编程”,以便它可以在宿主中定居。这对细菌是有益的,因为它可以在宿主中迅速繁殖,然后再被释放回环境中。在人类中,这一过程与称为霍乱的疾病有关。因此,了解霍乱弧菌如何适应不同的环境是非常有趣的。在最近的工作中,我们已经展示了如何应用下一代实验工具可以快速推进我们对细菌病原体的理解。我们建议应用这些工具来了解霍乱弧菌的生活方式转换。最终,通过分离生活方式转换的控制,并重新设计霍乱弧菌以不同的方式调节这一过程,我们希望刺激疫苗设计的新时代。我们希望这种方法将适用于许多由细菌引起的疾病。我们已经确定了可能从这些进步中受益的英国生物制药公司,并将在整个项目过程中与他们密切联系。这种互动的目的是最大限度地发挥我们工作的影响力,并利用商业化出现的机会。总之,我们将研究一种全球重要的病原体,并制定适用于控制所有细菌的策略。重要的是,这一应用是在人们正在寻找抗生素替代品的时候出现的,采取行动的机会之窗是敞开的。我们已经与我们数据的重要“最终用户”建立了联系,以最大限度地提高我们工作的经济影响。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Homologs of the Escherichia coli F Element Protein TraR, Including Phage Lambda Orf73, Directly Reprogram Host Transcription.
  • DOI:
    10.1128/mbio.00952-22
  • 发表时间:
    2022-06-28
  • 期刊:
  • 影响因子:
    6.4
  • 作者:
    Gopalkrishnan, Saumya;Ross, Wilma;Akbari, Madeline S.;Li, Xintian;Haycocks, James R. J.;Grainger, David C.;Court, Donald L.;Gourse, Richard L.
  • 通讯作者:
    Gourse, Richard L.
cAMP Receptor Protein Controls Vibrio cholerae Gene Expression in Response to Host Colonization.
  • DOI:
    10.1128/mbio.00966-18
  • 发表时间:
    2018-07-10
  • 期刊:
  • 影响因子:
    6.4
  • 作者:
    Manneh-Roussel J;Haycocks JRJ;Magán A;Perez-Soto N;Voelz K;Camilli A;Krachler AM;Grainger DC
  • 通讯作者:
    Grainger DC
Genome-wide mapping of Vibrio cholerae VpsT binding identifies a mechanism for c-di-GMP homeostasis
霍乱弧菌 VpsT 结合的全基因组图谱确定了 c-di-GMP 稳态机制
  • DOI:
    10.1101/2021.10.04.463056
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Guest T
  • 通讯作者:
    Guest T
Unusually Situated Binding Sites for Bacterial Transcription Factors Can Have Hidden Functionality.
  • DOI:
    10.1371/journal.pone.0157016
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Haycocks JR;Grainger DC
  • 通讯作者:
    Grainger DC
A dual-function RNA balances carbon uptake and central metabolism in Vibrio cholerae.
  • DOI:
    10.15252/embj.2021108542
  • 发表时间:
    2021-12-15
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Venkat K;Hoyos M;Haycocks JR;Cassidy L;Engelmann B;Rolle-Kampczyk U;von Bergen M;Tholey A;Grainger DC;Papenfort K
  • 通讯作者:
    Papenfort K
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Grainger其他文献

Translation of PET radiotracers for cancer imaging: recommendations from the National Cancer Imaging Translational Accelerator (NCITA) consensus meeting
  • DOI:
    10.1186/s12916-024-03831-z
  • 发表时间:
    2025-01-23
  • 期刊:
  • 影响因子:
    8.300
  • 作者:
    Martina A. McAteer;Daniel R. McGowan;Gary J. R. Cook;Hing Y. Leung;Tony Ng;James P. B. O’Connor;Luigi Aloj;Anna Barnes;Phil J. Blower;Kevin M. Brindle;John Braun;Craig Buckley;Daniel Darian;Paul Evans;Vicky Goh;David Grainger;Carol Green;Matt G. Hall;Thomas A. Harding;Catherine D. G. Hines;Simon J. Hollingsworth;Penny L. Hubbard Cristinacce;Rowland O. Illing;Martin Lee;Baptiste Leurent;Sue Mallett;Radhouene Neji;Natalia Norori;Nora Pashayan;Neel Patel;Kieran Prior;Thomas Reiner;Adam Retter;Alasdair Taylor;Jasper van der Aart;Joseph Woollcott;Wai-Lup Wong;Jan van der Meulen;Shonit Punwani;Geoff S. Higgins
  • 通讯作者:
    Geoff S. Higgins
Annual health outcomes and treatment costs for schizophrenia populations.
精神分裂症人群的年度健康结果和治疗费用。
  • DOI:
  • 发表时间:
    1999
  • 期刊:
  • 影响因子:
    5.3
  • 作者:
    Josephine Mauskopf;K. David;David Grainger;PJ Gibson
  • 通讯作者:
    PJ Gibson
P3.07-022 Progress against Non-Small-Cell Lung Cancer (NSCLC) Compared to Other Solid Tumors: Topic: Other – Geographical Differences
  • DOI:
    10.1016/j.jtho.2016.11.2213
  • 发表时间:
    2017-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Silvia Paddock;Samuel Thomas;Michael Peake;Jacqueline Zummo;David Grainger;Rose Li
  • 通讯作者:
    Rose Li
What do female medical students know about planned oocyte cryopreservation and what are their personal attitudes?
女医学生对计划卵母细胞冷冻保存了解多少?她们的个人态度是什么?
Blue hydrogen must be done properly
蓝氢一定要做好
  • DOI:
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    0
  • 作者:
    J. Pettersen;R. Steeneveldt;David Grainger;T. Scott;Louise‐Marie Holst;E. S. Hamborg
  • 通讯作者:
    E. S. Hamborg

David Grainger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Grainger', 18)}}的其他基金

Redefining rules for global gene control in bacteria
重新定义细菌全球基因控制规则
  • 批准号:
    BB/Y000536/1
  • 财政年份:
    2023
  • 资助金额:
    $ 45.02万
  • 项目类别:
    Research Grant
Redefining the rules - widespread bidirectional transcription from prokaryotic promoters
重新定义规则——原核启动子广泛的双向转录
  • 批准号:
    BB/W00688X/1
  • 财政年份:
    2022
  • 资助金额:
    $ 45.02万
  • 项目类别:
    Research Grant
Understanding multiple antibiotic resistance in Gram-negative bacteria
了解革兰氏阴性菌的多重抗生素耐药性
  • 批准号:
    BB/N014200/1
  • 财政年份:
    2016
  • 资助金额:
    $ 45.02万
  • 项目类别:
    Research Grant
Controlling chromosome structure in starved bacteria
控制饥饿细菌的染色体结构
  • 批准号:
    BB/H010289/2
  • 财政年份:
    2011
  • 资助金额:
    $ 45.02万
  • 项目类别:
    Research Grant
Controlling chromosome structure in starved bacteria
控制饥饿细菌的染色体结构
  • 批准号:
    BB/H010289/1
  • 财政年份:
    2010
  • 资助金额:
    $ 45.02万
  • 项目类别:
    Research Grant
NSF Young Investigator
NSF 青年研究员
  • 批准号:
    9596023
  • 财政年份:
    1994
  • 资助金额:
    $ 45.02万
  • 项目类别:
    Continuing Grant
Novel Polymer Affinity Membranes for Organic-Organic Pervaporation Separation
用于有机-有机渗透汽化分离的新型聚合物亲和膜
  • 批准号:
    9496311
  • 财政年份:
    1994
  • 资助金额:
    $ 45.02万
  • 项目类别:
    Continuing Grant
Polymeric Ultrathin Films as Bonded Lubricants, Coatings, and Membranes
聚合物超薄膜作为粘合润滑剂、涂层和膜
  • 批准号:
    9496265
  • 财政年份:
    1994
  • 资助金额:
    $ 45.02万
  • 项目类别:
    Standard Grant
Novel Polymer Affinity Membranes for Organic-Organic Pervaporation Separation
用于有机-有机渗透汽化分离的新型聚合物亲和膜
  • 批准号:
    9300190
  • 财政年份:
    1993
  • 资助金额:
    $ 45.02万
  • 项目类别:
    Continuing Grant
NSF Young Investigator
NSF 青年研究员
  • 批准号:
    9357439
  • 财政年份:
    1993
  • 资助金额:
    $ 45.02万
  • 项目类别:
    Continuing Grant

相似海外基金

Acetylation of virulence factor regulatory proteins in V. cholerae
霍乱弧菌毒力因子调节蛋白的乙酰化
  • 批准号:
    9896576
  • 财政年份:
    2020
  • 资助金额:
    $ 45.02万
  • 项目类别:
Effet de faibles concentrations en peptides antimicrobiens sur le chimiotactisme de V. cholerae
霍乱弧菌化学活性肽抗菌剂浓度的影响
  • 批准号:
    542120-2019
  • 财政年份:
    2019
  • 资助金额:
    $ 45.02万
  • 项目类别:
    University Undergraduate Student Research Awards
Novel effector protein functions encoded by T3SS positive V. cholerae
T3SS 阳性霍乱弧菌编码的新效应蛋白功能
  • 批准号:
    10199931
  • 财政年份:
    2017
  • 资助金额:
    $ 45.02万
  • 项目类别:
Innate and early B cell responses to V. cholerae
对霍乱弧菌的先天和早期 B 细胞反应
  • 批准号:
    8630383
  • 财政年份:
    2013
  • 资助金额:
    $ 45.02万
  • 项目类别:
Innate and early B cell responses to V. cholerae
对霍乱弧菌的先天和早期 B 细胞反应
  • 批准号:
    9185932
  • 财政年份:
    2013
  • 资助金额:
    $ 45.02万
  • 项目类别:
A Population-Level Analysis of Novel Antimicrobial Production Among Wild Marine V
野生海洋 V 中新型抗菌剂生产的群体水平分析
  • 批准号:
    8433969
  • 财政年份:
    2013
  • 资助金额:
    $ 45.02万
  • 项目类别:
Mechanistic Aspects of Actin Polymerization at WH2-proteins: Human Spir and VopF from V. cholerae in Comparison
WH2 蛋白肌动蛋白聚合的机制:人类 Spir 和来自霍乱弧菌的 VopF 的比较
  • 批准号:
    171084014
  • 财政年份:
    2010
  • 资助金额:
    $ 45.02万
  • 项目类别:
    Priority Programmes
V. cholerae proteins are required for biofilm growth-vaccine targets
生物膜生长疫苗靶标需要霍乱弧菌蛋白
  • 批准号:
    8142027
  • 财政年份:
    2010
  • 资助金额:
    $ 45.02万
  • 项目类别:
V. cholerae proteins are required for biofilm growth-vaccine targets
生物膜生长疫苗靶标需要霍乱弧菌蛋白
  • 批准号:
    7989810
  • 财政年份:
    2010
  • 资助金额:
    $ 45.02万
  • 项目类别:
Accessory toxin-mediated evasion of innate immunity during V. cholerae infection
霍乱弧菌感染期间辅助毒素介导的先天免疫逃避
  • 批准号:
    8063715
  • 财政年份:
    2010
  • 资助金额:
    $ 45.02万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了